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Abstract
Eighty-six carbapenem non-susceptible Pseudomonas aeruginosa isolates collected in the National Institute of Respiratory Diseases of
Mexico City were screened for the presence of metallo-b-lactamase (MBL) activity using both E-test strips and a microbiological assay
with EDTA-imipenem. Genomic comparisons and sequence analyses conducted with these isolates revealed the presence of blaVIM-2 in
two clonally related isolates, and blaIMP-15 in a clonally unrelated isolate. Both genes were found to be carried by class 1 integrons, and
blaIMP-15 was additionally present on a broad host-range plasmid. This is the ﬁrst report of co-existing P. aeruginosa strains producing
different MBLs in a Mexican hospital, highlighting the necessity of appropriate surveillance to prevent dissemination of carbapenem
resistance.
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Introduction
Metallo-b-lactamases (MBLs) represent a major emerging
antimicrobial resistance determinant among Pseudomonas
aeruginosa strains present in nosocomial infections [1,2]. Spe-
cial concern is raised by the occurrence of MBL genes within
particular genetic structures that also carry other antimicro-
bial resistance genes, known as integrons, as a result of their
wide potential for expression and dissemination [1–3]. Pseu-
domonas aeruginosa strains harbouring integrons possessing
different MBL genes appear to be common in many countries
of Asia, Europe and South America [2]. However, the pres-
ence in Mexico of MBL-bearing P. aeruginosa has been
detected only recently, and includes carbapenem-resistant
strains containing either blaIMP-18 or blaIMP-15, both
harboured in class 1 integrons [4–6]. These ﬁndings repre-
sent a worrying scenario that emphasizes the need for regio-
nal surveillance studies highlighting both the extent and
potential spread of this emerging mechanism of b-lactam
resistance [1]. In the present study, we report a 2-year
survey of MBLs prevalent among P. aeruginosa clinical isolates
in a teaching hospital in Mexico.
Materials and Methods
Bacterial isolates
The present study encompassed a total of 431 consecutive
P. aeruginosa isolates collected between 1 January 2004
and 31 December 2005 from patients attending the
National Institute of Respiratory Diseases, Mexico City.
Among these isolates, 336 (78%) were from clinical
samples obtained from inpatients, and the remainder (22%)
were obtained from outpatients. Of the 431 isolates, 368
(85.4%) were isolated from samples derived from
respiratory sources, 15 (3.5%) were from blood, and 48
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(11.1%) were from other clinical sources. Each isolate was
obtained from a different patient.
Bacterial species identiﬁcation and susceptibility testing
All P. aeruginosa isolates were identiﬁed by conventional
microbiological procedures. Bacterial susceptibility to differ-
ent antimicrobials, including imipenem, meropenem, amikacin,
ciproﬂoxacin, piperacillin-tazobactam, ticarcillin-clavulanic
acid, ceftazidime, cefepime and aztreonam, was evaluated
with the Sensititre ARIS system (Trek Diagnostic Systems,
East Grinstead, UK). Imipenem and meropenem susceptibility
were additionally tested with a standard broth microdilution
assay following the guidelines of the CLSI [7]. Pseudomonas
aeruginosa isolates producing MBLs were also tested with
the latter test employing all antimicrobials mentioned above.
Screening of MBL-producing strains
MBL producers were detected by two different procedures,
E-test MBL strips (AB Biodisk, Solna, Sweden), and the EDTA-
imipenem (EIM) microbiological assay using cell extracts [8].
For the latter, bacterial colonies were carefully removed from
the surface of a fresh overnight culture on a Mueller–Hinton
agar plate, and transferred to a pre-weighed 1.5-mL micro-
centrifuge tube until approximately 100 mg of wet cells were
collected. The cells were carefully suspended in 1 mL of
50 mM Tris–HCl (pH 8), recovered by centrifugation at
1500 g for 10 min, and the bacterial pellet was subjected to
ten cycles each consisting of 15 min of freezing at )20C
followed by 10 min of thawing at 37C. The extract thus
obtained was clariﬁed by centrifugation at 6000 g for 10 min,
and the supernatant was assayed for MBL activity as described
previously [8].
Identiﬁcation of MBL genes and integrons
The presence of blaVIM-like, blaIMP-like, and blaSPM-1 genes was
detected by PCR using primers described previously [8],
except in the case of blaIMP-like, where the reverse primer
used was IMP-19R (Table 1). Association of integrons with
MBL genes was investigated by PCR using a given pair of an
MBL gene-speciﬁc primer and an integron-speciﬁc primer
(Table 1). All PCR amplicons were sequenced at the
Sequencing Facility of the University of Maine (Orono, ME,
USA) and the corresponding genes were further identiﬁed
by database sequence similarity comparisons [9].
Pulsed-ﬁeld gel electrophoresis (PFGE)
Bacterial DNA was prepared as described by Barth et al. [10].
A contour-clamped homogeneous electric ﬁeld mapper sys-
tem (CHEF MAPPER; Bio-Rad, Hercules, CA, USA) was used
for PFGE to analyse SpeI (Invitrogen, Carlsbad, CA, USA)-
digested DNA at a voltage of 6 V/cm at 13C for 22 h, with
pulse times of 1–40 s. Gels were stained with ethidium bro-
mide, photographed and examined by Chemidoc XRS and
Quantity One software (Bio-Rad). PFGE patterns were inter-
preted in accordance with the guidelines of Tenover et al. [11].
Pseudomonas aeruginosa plasmid analysis
Plasmid DNA was extracted from MBL-producing P. aeruginosa
isolates by the alkaline-lysis method [12], and used to trans-
form electrocompetent Escherichia coli DH5a cells [12]. The
transformed bacteria were plated on Luria–Bertani agar sup-
plemented with 16 mg/L of ampicillin, and different clones
were collected for MBL production using the EIM assay [8].
In addition, MICs of ampicillin, cephalothin, cefoxitin,
ceftazidime, cefepime, imipenem, meropenem, aztreonam,
gentamicin, amikacin, ciproﬂoxacin and levoﬂoxacin were
determined for transformed E. coli cells using the standard
broth microdilution test [7].
The presence of blaIMP-15 in the above E. coli transfor-
mants was tested by PCR using the speciﬁc primers shown
in Table 1. Plasmids were extracted from these bacteria
by the alkaline lysis method described above, and further
characterized by EcoRI or HindIII digestion followed by elec-
trophoretic agarose gel (0.7%) analysis of the fragments [12].
Hybridization studies
Chromosomal or plasmid location of blaVIM-2 genes in P. aeru-
ginosa strain 918 was evaluated by Southern blot analysis as
described previously [12] with a 32P-labelled probe generated
by PCR using blaVIM-2-speciﬁc primers (Table 1). Total DNA
from this bacterial strain was puriﬁed as described previously
[12] and further digested with HindIII, EcoRI, BamHI or PstI
(Invitrogen) in accordance with the manufacturer’s instruc-
tions. The resulting fragments were then separated by 0.7%
agarose gel electrophoresis and transferred to nylon mem-
branes (Hybond; Amersham Pharmacia Biotech, Piscataway,
NJ, USA) for Southern analysis. Plasmid DNA was extracted
by the alkaline lysis method [12], digested with the restric-
TABLE 1. Sequences of primers used in the present study
Target
gene or
region
Primers
(5¢–3¢)a
Expected
PCR
product
(pb) Reference
blaIMP-like IMP1-F GAGCAAGTTATYTGTATTCT
IMP19-R TCYMAHGTAMGYTTCAAGAG
664 Present study
blaVIM-like VIM-F ATTGGTCTATTTGACCGCGT
VIM-R CTACTCAACGACTGAGCGAT
778 8
blaSPM-1 SPM-F GGCGCGTTTTGTTTGTTG
SPM-R CTACAGTCTCATTTCGCCAACG
770 8
5¢-CS INT1-F GGCATCCAAGCAGCAAG – 19
3¢-CS INT1-R AAGCAGACTTGACCTGA – 19
aY: C, T; M: A, C; H: A, T, C.
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tion enzymes indicated above, and treated as above for
Southern analysis. Digestion of plasmid samples to remove
chromosomal DNA contamination was carried out with
ExoIII nuclease (Takara Bio, Inc., Tokyo, Japan) treatment in
accordance with previously described procedures [12].
Southern blots were analysed in a Storm Phosphorimager
840 (GE Healthcare, Piscataway, NJ, USA) in accordance
with the manufacturer’s instructions.
Results and Discussion
From a total of 431 P. aeruginosa clinical isolates collected dur-
ing the 2-year period (2004–2005) of the study, 86 (19.9%)
were considered as non-susceptible to imipenem and merope-
nem on the basis of their MIC values (breakpoint of > 4 mg/L).
From these, only three isolates (numbers 70, 918 and
4401; Table 2) tested positive for MBL activity using the EIM
assay [8]. Similarly, E-test MBL strip testing indicated the
presence of MBLs as judged by the EDTA effect on the cor-
responding MICs of imipenem; for isolate 70, the MIC was
reduced from 96 to 6 mg/L, for isolate 918, the MIC was
reduced from 64 to 1 mg/L, and, for isolate 4401, the MIC
was reduced from from 32 to 1 mg/L, in the absence vs. the
presence of EDTA in each case. Admission dates, clinical
characteristics, and outcome for the different patients
infected by these strains are shown in Table 2.
The presence of blaVIM-like, blaIMP-like and blaSPM-1 in P. aeru-
ginosa strains 70, 918 and 4401 was evaluated by PCR. Further
conﬁrmation of the identity of the corresponding genes after
DNA sequencing and database sequence similarity compari-
sons revealed that P. aeruginosa strains 918 and 4401 both car-
ried blaVIM-2, and that P. aeruginosa 70 contained blaIMP-15.
The genomic relatedness of the P. aeruginosa strains was
evaluated by PFGE of SpeI-digested DNA samples. The
restriction patterns thus obtained indicated no genomic
difference between blaVIM-2-containing isolates 918 and 4401
(designated as clone B in Table 2; Fig. 1, lanes 2 and 3), there-
fore suggesting the dissemination of this clone in the hospital.
The restriction proﬁle of the blaIMP-15-containing P. aeruginosa
70 (designated clone A in Table 2; Fig. 1, lane 1) was clearly
different from that of clone B, indicating the presence of two
non-related, co-existing P. aeruginosa strains producing
different MBLs in this hospital.
Because blaVIM and blaIMP genes are mainly found within
class 1 integrons [2,3], we subsequently analysed whether
the same situation occurred for the blaIMP-15 and blaVIM-2
genes detected in the above P. aeruginosa strains. This was
carried out by PCR using 5¢-CS as the direct primer
(designed after the 5¢-conserved segment of class 1 integ-
rons) and either IMP-19R or VIM-R in the case of P. aerugin-
osa strains 70 or 918 as the corresponding reverse primer,
respectively (Table 1). In both cases, one main PCR product
TABLE 2. Clinical features of MBL-producing Pseudomonas aeruginosa clinical isolates used in the present study
Isolatea
Collection
date
Site of
infection
Days of
hospitalization
Previous
antibiotics
Response to
treatment
Clinical
outcome
PFGE
pattern
MIC (mg/L)
AMK CIP CAZ FEP TZP TIC ATM IPM
70 05-01-05 Lung 5 None Favorable Alive A >256 >32 >32 >256 32 >256 16 128
918 10-02-05 Blood 25 Cefepime
Amikacin
No response Died B 16 0.25 >32 16 64 >256 16 64
4401 21-06-05 Lung 91 Cefepime
Clindamycin
Favorable Alive B 128 >32 16 16 32 64 16 32
aThe three isolates came from three different patients.
PGFE, pulsed-ﬁeld gel electrophoresis; AMK, amikacin; CIP, ciproﬂoxacin; CAZ, ceftazidime; FEP, cefepime; TZP, piperacillin-tazobactam; TIC, ticarcillin-clavulanic acid; ATM,
aztreonam; IPM, imipenem.
MIC values were determined by broth microdilution assay [7].
FIG. 1. Pulsed-ﬁeld gel electrophoresis proﬁles of SpeI-digested
genomic DNA from Pseudomonas aeruginosa strains carrying the MBL
genes under investigation. Lane 1, strain 70 carrying blaIMP-15; lanes 2
and 3, strains 918 and 4401, respectively, both carrying blaVIM-2. M,
Pulse Marker, a mixture of Lambda DNA HindIII fragments, Lambda
DNA, and Lambda concatemers covering a 0.1–200 kbp range (Krac-
keler Scientiﬁc, Inc., Albany, NY, USA).
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was obtained, and subsequent analyses [9] revealed that, in
P. aeruginosa strain 70, blaIMP-15 is present in a class 1 integ-
ron preceded by an aminoglycoside acetyltransferase gene
(aacA7) located immediately downstream of the conserved
5¢-segment of this element. It is noteworthy that this
sequence is identical to the 5¢ region of the In95 class 1 in-
tegron recently described in Mexican hospitals, but differs
from the equivalent region found in other blaIMP-15-containing
integrons described in other parts of the world, such as
Thailand [5].
In the case of P. aeruginosa strain 918, blaVIM-2 is also pres-
ent in a class 1 integron, representing the ﬁrst resistance
gene present immediately adjacent to the 5¢-conserved seg-
ment of the element. This is exactly the position found for
the equivalent gene in class 1 integrons in other P. aeruginosa
strains that have been described in different regions of Latin
America [13], but it differs from that in the class 1 integrons
characterized in other geographic areas, including Europe,
Asia or the USA [3,14,15]. This gene arrangement found in
class 1 integrons in Latin America is therefore worthy of
note in the light of the fact that VIM-2 was ﬁrst described
only recently in this geographic area [13].
We next analysed the possibility that the above integrons
could be harbored by plasmids. For this purpose, P. aeruginosa
70, 918 and 4401 were subjected to the alkaline-lysis method
of plasmid extraction [12], and the material thus obtained
was subsequently transformed into electrocompetent E. coli
DH5a cells. The transformed bacteria were plated onto
Luria–Bertani nutrient agar containing 16 mg/L of ampicillin,
and selected clones were analysed for antimicrobial suscepti-
bility and the presence of plasmids.
As shown in Table 3, E. coli cells transformed with plas-
mids derived from P. aeruginosa 70 (which carries a class 1
integron containing aacA7 and blaIMP-15 genes; see above)
demonstrated decreased susceptibility to all b-lactams tested
(with the exception of aztreonam) and also to amikacin.
Indeed, MIC values for the transformed cells (relative to
non-transformed bacteria) increased as follows: by 128-fold
in the case of ceftazidime, 16-fold for cefepime, 8-fold for
cephalothin and cefoxitin, 4-fold for ampicillin and mero-
penem, and 2-fold for imipenem and amikacin. By contrast,
bacterial susceptibility to gentamicin, ciproﬂoxacin and levo-
ﬂoxacin remained unchanged (Table 3).
The overall results indicated that the class 1 integron
present in P. aeruginosa 70 is borne on a broad host-range
plasmid. In agreement, restriction enzyme analysis revealed
the presence in the transformed E. coli cells of a plasmid of
a size estimated at c. 30 kbp (Fig. S1). PCR assays with
blaIMP-speciﬁc primers (see above) further conﬁrmed the
presence of blaIMP-15 in this plasmid, which was designated
pMX70. The ability of pMX70 to direct expression of
blaIMP-15 in E. coli was further tested by the EIM assay using
bacterial extracts [8]. Hydrolysis of imipenem and inhibition
by EDTA in this assay further conﬁrmed MBL production by
pMX70-transformed E. coli cells.
Transformation of E. coli cells with plasmids derived from
P. aeruginosa strain 918, which carries a class 1 integron con-
taining blaVIM-2 (see above), consistently failed to generate
ampicillin-resistant bacteria. We thus evaluated by Southern
blot analysis whether the blaVIM-2 gene is located in the chro-
mosome or in plasmids present in this particular strain
(Fig. S2). An analysis was conducted on total DNA as well as
on plasmids puriﬁed from this bacterial strain, both digested
with several restriction enzymes using 32P-labelled blaVIM-2 as
a probe. Clear positive signals were observed in samples
derived from restriction enzyme treatments on total DNA
(lanes 2–5). Moreover, treatment with ExoIII nuclease totally
abolished labelling (lane 1), as expected from the presence of
the blaVIM-2 gene in linear DNA fragments that result from
chromosome shearing during extraction [12]. In agreement,
very weak to no signals were observed in plasmid samples
that were treated similarly (lanes 6–11).
The overall results indicate that blaVIM-2 is located in the
chromosome of P. aeruginosa strain 918. Furthermore, they
provide experimental support to previous proposals made in
other studies [13] that blaVIM-2 genes in P. aeruginosa strains
present in Latin America are most likely to be chromosome-
borne rather than carried on plasmids. It is also relevant that
bi-parental conjugation assays conducted between P. aerugin-
osa strains 70, 918 or 4401 (serving as DNA donors) and
rifampicin-resistant E. coli DH5a as DNA recipient [16]
consistently failed to indicate the transfer of ampicillin
resistance, thereby reinforcing the above conclusions.
TABLE 3. Comparison of MICs of different antimicrobial
agents for Escherichia coli DH5a (control cells) and E. coli
DH5a (pMX70)
Antimicrobial
tested
MIC (mg/L)
Control cells
Escherichia
coli (pMX70)
Ampicillin 8 32
Cephalothin 4 32
Cefoxitin 4 32
Ceftazidime 0.25 32
Cefepime 0.06 1
Imipenem 0.12 0.25
Meropenem 0.03 0.12
Aztreonam 0.25 0.25
Gentamicin 1 1
Amikacina 2 4
Ciproﬂoxacin 0.25 0.25
Levoﬂoxacin 0.25 0.25
aSequencing analysis indicates that pMX70 bears a class 1 integron containing
aacA7 besides blaIMP-15.
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The emergence of carbapenem resistance is of particular
concern in the treatment of P. aeruginosa infections because
these antimicrobials constitute the last resort for the
treatment of this life-threatening pathogen [17,18]. Reports
of acquired MBLs among non-fermentative bacterial patho-
gens are increasing worldwide, although their prevalence in
Latin America is so far limited [2,13]. The present study is
the ﬁrst to uncover the presence of co-existing P. aeruginosa
strains producing different MBLs in the National Institute of
Respiratory Diseases of Mexico City. The prevalence of
these enzymes was 3.5% among carbapenem-non-susceptible
P. aeruginosa isolates collected in this institution (3/86 iso-
lates). Among them, blaVIM-2 was present in two clonally
related isolates, and the recently described blaIMP-15 was
identiﬁed in a clonally unrelated isolate. Most importantly,
both blaVIM-2 and blaIMP-15 are harboured in these P. aerugin-
osa strains by class 1 integrons, and blaIMP-15 additionally is
present on a broad host-range plasmid; all in all, these com-
prise worrying scenarios that demand mandatory surveillance
to prevent the generalized spread of carbapenem resistance.
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Fig. S1. Restriction analysis of pMX70. The plasmid was
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enzymes indicated below and the fragments were separated
by electrophorosis in 0.7% agarose. Lane 1: HindIII; lane 2:
EcoRI; lane 3: non-digested pMX70. The ﬁnal positions of
the corresponding size markers (EcoRI/HindIII-digested k
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described in ref [13].
Fig. S2. Location of blaVIM-2 in P. aeruginosa strain 918.
A. Agarose gel electrophorosis/ethidium bromide staining.
B. Southern hybridization analysis using a 32P-labeled blaVIM-2
probe. Lane 1: ExoIII nuclease-digested chromosomal DNA;
lane 2 to 5: HindIII-EcoRI-BamHI and Pstl digested chromo-
somal DNA. respectively; lane 6: plasmids extracted from
P.aeruginosa strain 918; lane 7: ExoIII nuclease-digested
plasmidic DNA; lane 8 to 11: HindIII,EcoRI-,BamHI- and
Pstl-digested plasmidic DNA, respectively. The size (in bp) of
fragments derived from EcoRI/HindIII-digested k DNA.
Indicated in the left margin.
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